Cognition Therapeutics Inc [NASDAQ: CGTX] gained 10.28% or 0.06 points to close at $0.68 with a heavy trading volume of 5139446 shares.
It opened the trading session at $0.6456, the shares rose to $0.6884 and dropped to $0.625, the range by which the price of stock traded the whole day. The daily chart for CGTX points out that the company has recorded -4.76% loss over the past six months.
If we look at the average trading volume of 6.90M shares, CGTX reached to a volume of 5139446 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Cognition Therapeutics Inc [CGTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CGTX shares is $3.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CGTX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley Securities have made an estimate for Cognition Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 19, 2024. The new note on the price target was released on July 30, 2024, representing the official price target for Cognition Therapeutics Inc stock. Previously, the target price had yet another raise to $22, while Oppenheimer analysts kept a Outperform rating on CGTX stock.
The Price to Book ratio for the last quarter was 3.43, with the Price to Cash per share for the same quarter was set at 0.27.
Trading performance analysis for CGTX stock
Cognition Therapeutics Inc [CGTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.82. With this latest performance, CGTX shares gained by 111.18% in over the last four-week period, additionally sinking by -4.76% over the last 6 months – not to mention a drop of -3.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CGTX stock in for the last two-week period is set at 67.96, with the RSI for the last a single of trading hit 0.1039, and the three-weeks RSI is set at 0.0769 for Cognition Therapeutics Inc [CGTX]. The present Moving Average for the last 50 days of trading for this stock 0.3619, while it was recorded at 0.6074 for the last single week of trading, and 0.4761 for the last 200 days.
Cognition Therapeutics Inc (CGTX) Capital Structure & Debt Analysis
According to recent financial data for Cognition Therapeutics Inc. ( CGTX), the Return on Equity (ROE) stands at -161.93%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -106.81%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Cognition Therapeutics Inc’s Return on Invested Capital (ROIC) is -265.34%, showcasing its effectiveness in deploying capital for earnings.
Cognition Therapeutics Inc (CGTX) Efficiency & Liquidity Metrics
Based on Cognition Therapeutics Inc’s (CGTX) latest financial statements, the Debt-to-Equity Ratio is 0.04%, indicating its reliance on debt financing relative to shareholder equity.
Cognition Therapeutics Inc (CGTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Cognition Therapeutics Inc. (CGTX) effectively leverages its workforce, generating an average of -$1189285.71 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.09% and a Quick Ratio of 2.09%, indicating strong ability to cover short-term liabilities.
Cognition Therapeutics Inc [CGTX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CGTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cognition Therapeutics Inc go to 32.88%.
An analysis of Institutional ownership at Cognition Therapeutics Inc [CGTX]
There are presently around $18.79%, or 18.94% of CGTX stock, in the hands of institutional investors. The top three institutional holders of CGTX stocks are: VANGUARD GROUP INC with ownership of 1.15 million shares, which is approximately 2.8644%. AWM INVESTMENT COMPANY, INC., holding 0.65 million shares of the stock with an approximate value of $$1.08 million in CGTX stocks shares; and AWM INVESTMENT COMPANY, INC., currently with $$0.83 million in CGTX stock with ownership which is approximately 1.248%.
